Viruses (Oct 2020)

Increasing Prevalence of HIV-1 Transmitted Drug Resistance in Portugal: Implications for First Line Treatment Recommendations

  • Marta Pingarilho,
  • Victor Pimentel,
  • Isabel Diogo,
  • Sandra Fernandes,
  • Mafalda Miranda,
  • Andrea Pineda-Pena,
  • Pieter Libin,
  • Kristof Theys,
  • M. Rosário O. Martins,
  • Anne-Mieke Vandamme,
  • Ricardo Camacho,
  • Perpétua Gomes,
  • Ana Abecasis,
  • on behalf of the Portuguese HIV-1 Resistance Study Group

DOI
https://doi.org/10.3390/v12111238
Journal volume & issue
Vol. 12, no. 11
p. 1238

Abstract

Read online

Introduction: Treatment for All recommendations have allowed access to antiretroviral (ARV) treatment for an increasing number of patients. This minimizes the transmission of infection but can potentiate the risk of transmitted (TDR) and acquired drug resistance (ADR). Objective: To study the trends of TDR and ADR in patients followed up in Portuguese hospitals between 2001 and 2017. Methods: In total, 11,911 patients of the Portuguese REGA database were included. TDR was defined as the presence of one or more surveillance drug resistance mutation according to the WHO surveillance list. Genotypic resistance to ARV was evaluated with Stanford HIVdb v7.0. Patterns of TDR, ADR and the prevalence of mutations over time were analyzed using logistic regression. Results and Discussion: The prevalence of TDR increased from 7.9% in 2003 to 13.1% in 2017 (p p = 0.002) and 2.9% to 8.9% (p p p p < 0.001). Conclusions: While ADR has been decreasing since 2001, TDR has been increasing, reaching a value of 13.1% by the end of 2017. It is urgently necessary to develop public health programs to monitor the levels and patterns of TDR in newly diagnosed patients.

Keywords